Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de guselkumab en participantes pediátricos con enfermedad de Crohn activa de moderada a grave (MACARONI-23)

2 de noviembre de 2026 actualizado por: Janssen Research & Development, LLC

Un estudio de plataforma de fase 3, multicéntrico, aleatorizado, de la inhibición de p19 de la vía IL-23 para establecer la eficacia en la enfermedad de Crohn pediátrica

The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

120

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Nedlands, Australia, 6009
        • Reclutamiento
        • Perth Children's Hospital
      • South Brisbane, Australia, 4101
        • Reclutamiento
        • Mater Hospital Brisbane
      • Westmead, Australia, 2145
        • Reclutamiento
        • The Children's Hospital at Westmead
      • Vienna, Austria, 1090
        • Reclutamiento
        • AKH - Medizinische Universitat Wien
      • Campinas, Brasil, 13060-904
        • Reclutamiento
        • Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro
      • Curitiba, Brasil, 80250-060
        • Reclutamiento
        • Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro
      • Goiânia, Brasil, 74605-020
        • Reclutamiento
        • Universidade Federal de Goias - Hospital das Clinicas da UFG
      • Porto Alegre, Brasil, 90035-074
        • Reclutamiento
        • Irmandade Santa Casa de Misericordia de Porto Alegre
      • Porto Alegre, Brasil, 90035-007
        • Reclutamiento
        • Hospital De Clinicas De Porto Alegre
      • Vitória, Brasil, 29040-091
        • Reclutamiento
        • Centro de Ciencias e Saude da Universidade Federal do Espirito Santo-Nucleo de Doencas Infecciosas
      • Votuporanga, Brasil, 100000
        • Reclutamiento
        • INTEGRAL Pesquisa e Ensino
      • Brussels, Bélgica, 1090
        • Reclutamiento
        • Universitair Ziekenhuis Brussel
      • Brussels, Bélgica, 1200
        • Reclutamiento
        • Cliniques Universitaires Saint Luc
      • Ghent, Bélgica, 9000
        • Reclutamiento
        • Universitair Ziekenhuis Gent
      • Leuven, Bélgica, 3000
        • Reclutamiento
        • UZ Leuven
    • Nova Scotia
      • Halifax, Nova Scotia, Canadá, B3K 6R8
        • Reclutamiento
        • Iwk Health Centre
    • Ontario
      • London, Ontario, Canadá, N6A 5W9
        • Reclutamiento
        • London Health Sciences Centre Victoria Hospital
      • Toronto, Ontario, Canadá, M5G 1X8
        • Reclutamiento
        • Hospital For Sick Children
      • Busan, Corea del Sur, 48108
        • Reclutamiento
        • Inje University Haeundae Paik Hospital
      • Daegu, Corea del Sur, 41404
        • Reclutamiento
        • Kyungpook National University Chilgok Hospital
      • Seoul, Corea del Sur, 03080
        • Reclutamiento
        • Seoul National University Hospital
      • Seoul, Corea del Sur, 06351
        • Reclutamiento
        • Samsung Medical Center
      • Seoul, Corea del Sur, 120-752
        • Reclutamiento
        • Severance Hospital Yonsei University Health System
      • Córdoba, España, 14004
        • Reclutamiento
        • Hosp Reina Sofia
      • Sabadell, España, 8208
        • Reclutamiento
        • Corporacio Sanitari Parc Tauli
      • Valencia, España, 46026
        • Reclutamiento
        • Hosp. Univ. I Politecni La Fe
    • California
      • Los Angeles, California, Estados Unidos, 90048
        • Reclutamiento
        • Cedars Sinai Medical Center
    • Connecticut
      • Hartford, Connecticut, Estados Unidos, 06106
        • Reclutamiento
        • Connecticut Children's Medical Center
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Reclutamiento
        • Emory University
      • Atlanta, Georgia, Estados Unidos, 30342
        • Reclutamiento
        • Children's Center for Digestive Health Care
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202-5225
        • Reclutamiento
        • Riley Hospital for Children
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Reclutamiento
        • Boston Childrens Hospital
    • New Jersey
      • Morristown, New Jersey, Estados Unidos, 07960
        • Reclutamiento
        • Goryeb Children's Hospital
    • New York
      • New York, New York, Estados Unidos, 10029
        • Reclutamiento
        • Icahn School of Medicine at Mount Sinai
      • New York, New York, Estados Unidos, 10032
        • Reclutamiento
        • Columbia University Medical Center
      • New York, New York, Estados Unidos, 10021-5663
        • Reclutamiento
        • Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
    • Ohio
      • Dayton, Ohio, Estados Unidos, 45404
        • Reclutamiento
        • The Children's Medical Center of Dayton
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Reclutamiento
        • Children's Hospital of Philadelphia
    • Texas
      • Fort Worth, Texas, Estados Unidos, 76104
        • Reclutamiento
        • Cook Childrens Medical Center
    • Vermont
      • Colchester, Vermont, Estados Unidos, 05446
        • Reclutamiento
        • University of Vermont Medical Center
      • Amiens, Francia, 80054
        • Reclutamiento
        • CHU Amiens-Hopital Nord
      • Lille, Francia, 59037
        • Reclutamiento
        • Hôpital Jeanne de FLANDRE, CHRU LILLE
      • Paris, Francia, 75019
        • Reclutamiento
        • Hôpital Robert Debré
      • Paris, Francia, 75015
        • Reclutamiento
        • Hôpital Necker - Enfants Malades
      • Beersheba, Israel, 84101
        • Reclutamiento
        • Soroka University Medical Center
      • Be’er Ya‘aqov, Israel, 70300
        • Reclutamiento
        • Shamir Medical Center Assaf Harofeh
      • Jerusalem, Israel, 9103102
        • Reclutamiento
        • Shaare Zedek Medical Center
      • Jerusalem, Israel, 9124001
        • Reclutamiento
        • Hadassah Medical Center
      • Petah Tikva, Israel, 4920235
        • Reclutamiento
        • Schneider Children's Medical Center
      • Rehovot, Israel, 761001
        • Reclutamiento
        • Kaplan Medical Center
      • Alessandria, Italia, 15121
        • Reclutamiento
        • A.O. Santi Antonio e Biagio e Cesare Arrigo
      • Bergamo, Italia, 24127
        • Reclutamiento
        • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
      • Bologna, Italia, 40124
        • Reclutamiento
        • Ospedale Bellaria, U.O.Cardiologia Az. USL di Bologna
      • Florence, Italia, 50139
        • Reclutamiento
        • Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
      • Milan, Italia, 20154
        • Reclutamiento
        • Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale dei Bambini Vittore Buzzi
      • Roma, Italia, 161
        • Reclutamiento
        • AOU Policlinico Umberto I
      • Hirosaki, Japón, 036-8563
        • Reclutamiento
        • Hirosaki University Hospital
      • Kagoshima, Japón, 890-8544
        • Reclutamiento
        • Kagoshima University Hospital
      • Kashiwa-shi, Japón, 277-0871
        • Reclutamiento
        • Tsujinaka Hospital Kashiwanoha
      • Kobe, Japón, 650 0017
        • Reclutamiento
        • Kobe University Hospital
      • Saga, Japón, 849-8501
        • Reclutamiento
        • Saga University Hospital
      • Sendai, Japón, 989-3126
        • Reclutamiento
        • Miyagi Childrens Hospital
      • Setagaya Ku, Japón, 157 8535
        • Reclutamiento
        • National Center for Child Health and Development
      • Tokyo, Japón, 113-8431
        • Reclutamiento
        • Juntendo University Hospital
      • Tsu, Japón, 514 8507
        • Reclutamiento
        • Mie University Hospital
      • Ube, Japón, 755-8505
        • Reclutamiento
        • Yamaguchi University Hospital
      • Yokohama, Japón, 232-0024
        • Reclutamiento
        • Yokohama City University Medical Center
      • Yokohama, Japón, 230-8765
        • Reclutamiento
        • Saiseikai Yokohamashi Tobu Hospital
      • Nordbyhagen, Noruega, 1474
        • Reclutamiento
        • Akershus Universitetssykehus HF
      • Oslo, Noruega, 424
        • Reclutamiento
        • Oslo University Hospital
      • Tromsø, Noruega, 9038
        • Reclutamiento
        • Universitetssykehuset Nord-Norge HF
      • Trondheim, Noruega, 7030
        • Reclutamiento
        • St. Olavs Hospital
      • Rotterdam, Países Bajos, 3015 GD
        • Reclutamiento
        • Erasmus Medisch Centrum
      • Rzeszów, Polonia, 35-302
        • Reclutamiento
        • Korczowski Bartosz Gabinet Lekarski
      • Warsaw, Polonia, 04 501
        • Reclutamiento
        • WIP Warsaw IBD Point Profesor Kierkus
      • Warsaw, Polonia, 04 730
        • Reclutamiento
        • Instytut Pomnik Centrum Zdrowia
      • Braga, Portugal, 4710-243
        • Reclutamiento
        • Hospital de Braga
      • Lisbon, Portugal, 1649-035
        • Reclutamiento
        • Centro Hospitalar de Lisboa Norte Hospital Santa Maria
      • Porto, Portugal, 4200-319
        • Reclutamiento
        • Centro Hospitalar de Sao Joao E.P.E.
      • Glasgow, Reino Unido, G51 4TF
        • Reclutamiento
        • Royal Hospital for Sick Children
      • London, Reino Unido, WC1N 3JH
        • Reclutamiento
        • Great Ormond Street Hospital
      • Manchester, Reino Unido, M13 9WL
        • Reclutamiento
        • Royal Manchester Children's Hospital
      • Manchester, Reino Unido, M13 9WL
        • Reclutamiento
        • Nowgen Centre, Research and Innovation
      • Oxford, Reino Unido, OX3 9DU
        • Reclutamiento
        • John Radcliffe Hospital
      • Sheffield, Reino Unido, S10 2TH
        • Reclutamiento
        • Sheffield Children's Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

2 años a 17 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
  • Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=] 30)
  • Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
  • Participants must have a history of inadequate response, loss of response, or intolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV corticosteroids, or biologic therapy/JAK inhibitor therapy; OR have a history of corticosteroid dependence; OR have a history of inadequate response to exclusive enteral nutrition (EEN)

Exclusion Criteria:

  • Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery.
  • Participants must not have an abscess
  • Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Open-label induction phase: Guselkumab Intravenously (IV)

Participants will receive guselkumab dose IV based on their body weight during the 12-week open-label induction phase.

Guselkumab will be administered subcutaneously.

Otros nombres:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Otros nombres:
  • CNTO1959
  • TREMFYA
Experimental: Open-label induction phase: Guselkumab Subcutaneously (SC)

Participants will receive guselkumab dose SC based on their body weight during the 12-week open-label induction phase.

Guselkumab will be administered subcutaneously.

Otros nombres:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Otros nombres:
  • CNTO1959
  • TREMFYA
Experimental: Double-blind maintenance phase: Guselkumab SC Dose Regimen 1

At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Otros nombres:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Otros nombres:
  • CNTO1959
  • TREMFYA
Experimental: Double-blind Maintenance Phase: Guselkumab SC Dose Regimen 2

At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Otros nombres:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Otros nombres:
  • CNTO1959
  • TREMFYA
Experimental: Open-label maintenance phase: Guselkumab SC

Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Otros nombres:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Otros nombres:
  • CNTO1959
  • TREMFYA

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants with Clinical Remission at Week 52
Periodo de tiempo: Week 52

Percentage of participants with clinical remission at Week 52 will be assessed. Clinical remission is defined as pediatric Crohn's Disease activity index (PCDAI) less than or equal to (<=) 10.

Week 52
Percentage of Participants Who Achieve Endoscopic Response at Week 52
Periodo de tiempo: Week 52

Percentage of participants who achieve endoscopic response at Week 52 will be assessed. Endoscopic response is defined as greater than or equal to (>=) 50 percent (%) reduction (global) and greater than (>) 50% reduction (U.S specific) from simplified endoscopic score-Crohn's Disease (SES-CD) score at baseline.

Week 52

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants with Clinical Response at Week 12
Periodo de tiempo: Week 12

Percentage of participants with clinical response at Week 12 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30.

Week 12
Percentage of Participants with Clinical Response at Week 52
Periodo de tiempo: Week 52

Percentage of participants with clinical response at Week 52 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30.

Week 52
Percentage of Participants with Clinical Remission at Week 12
Periodo de tiempo: Week 12

Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is defined as PCDAI score <=10.

Week 12
Percentage of Participants with Endoscopic Remission at Week 52
Periodo de tiempo: Week 52

Percentage of participants with endoscopic remission at Week 52 will be assessed. Endoscopic remission is defined as SES-CD total score <=4 and at least a 2-point reduction from baseline and no subscore >1.

Week 52
Percentage of Participants with Corticosteroid-free Remission at Week 52
Periodo de tiempo: Week 52

Percentage of participants with corticosteroid-free remission at Week 52 will be assessed. Corticosteroid-free remission is defined as PCDAI score <=10 at Week 52 and not receiving corticosteroids for at least 90 days before Week 52.

Week 52
Percentage of Participants with Sustained Clinical Remission at Weeks 12, 24, and 52
Periodo de tiempo: Weeks 12, 24, and 52

Percentage of participants with sustained clinical remission at Weeks 12, 24, and 52 will be assessed. Sustained clinical remission is defined as PCDAI <=10 at Weeks 12, 24, and 52.

Weeks 12, 24, and 52
Percentage of Participants with Clinical remission by Patient-Reported Outcome (PRO-2)
Periodo de tiempo: Week 12 and/or Week 52

Percentage of participants with clinical remission by PRO-2 will be assessed. Clinical remission by PRO-2 is defined as stool frequency (SF) <=3 and abdominal pain (AP) <=1 and no worsening of SF and AP from baseline.

Week 12 and/or Week 52
Serum Concentration of Guselkumab During Induction Phase
Periodo de tiempo: From Week 0 to Week 12

Serum concentrations of guselkumab will be assessed. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive immunoassay method.

From Week 0 to Week 12
Trough Plasma Concentration (Ctrough) of Guselkumab During Maintenance Phase
Periodo de tiempo: At Weeks 16, 24, 36, 48 and 52

Ctrough is defined as the serum concentration of guselkumab immediately prior (pre-dose) to the next drug administration.

At Weeks 16, 24, 36, 48 and 52
Change from Baseline in Body Weight at Weeks 12, 24, and 52
Periodo de tiempo: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Body Weight Percentiles at Weeks 12, 24, and 52
Periodo de tiempo: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight percentiles at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Body Weight z-scores at Weeks 12, 24, and 52
Periodo de tiempo: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight z-scores at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height at Weeks 12, 24, and 52
Periodo de tiempo: Baseline, Weeks 12, 24, and 52

Change from baseline in height at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height Percentiles at Weeks 12, 24, and 52
Periodo de tiempo: Baseline, Weeks 12, 24, and 52

Change from baseline in height percentiles at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height z-scores at Weeks 12, 24, and 52
Periodo de tiempo: Baseline, Weeks 12, 24, and 52

Change from baseline in height z-scores at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height Velocity at Weeks 12, 24, and 52
Periodo de tiempo: Baseline, Weeks 12, 24, and 52

Change from baseline in height velocity at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Percentage of Participants with Clinical Remission
Periodo de tiempo: Week 52

Percentage of participants with clinical remission who were assigned to guselkumab dose regimen 1 and did not receive rescue therapy at Week 52 will be assessed. Clinical remission is defined as PCDAI score <=10.

Week 52
Percentage of Participants Who Achieve Endoscopic Response
Periodo de tiempo: Week 52

Percentage of participants who achieve endoscopic response who were assigned to q4w maintenance therapy and did not receive rescue therapy at Week 52 will be assessed. Endoscopic response is defined as >=50% reduction (global) and >50% reduction (U.S specific) from SES-CD score at baseline.

Week 52
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: Up to Week 64

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.

Up to Week 64

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Clinical Trial, Janssen Research & Development, LLC

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

13 de marzo de 2024

Finalización primaria (Estimado)

27 de octubre de 2027

Finalización del estudio (Estimado)

14 de agosto de 2028

Fechas de registro del estudio

Enviado por primera vez

20 de junio de 2023

Primero enviado que cumplió con los criterios de control de calidad

20 de junio de 2023

Publicado por primera vez (Actual)

28 de junio de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CR109212
  • 2021-006282-37 (Número EudraCT)
  • CNTO1959PBCRD3007 (Otro identificador: Janssen Research & Development, LLC)
  • 2023-504735-41-00 (Identificador de registro: EUCT number)
  • 2023 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .